The possible potentiating role of endoplasmic reticulum stress response inhibitors in trans-differentiation of white to brown adipocytes  by Sharifi, Ali Mohammad & Mottaghi, Sayeh
Journal of Medical Hypotheses and Ideas (2012) 6, 58–61Available online at www.sciencedirect.com
Journal of Medical Hypotheses and Ideas
journal homepage: www.elsevier.com/locate/jmhiREGULAR ARTICLESThe possible potentiating role of endoplasmic reticulum
stress response inhibitors in trans-diﬀerentiation of white
to brown adipocytesAli Mohammad Shariﬁ a,b,c,*, Sayeh Mottaghi aa Razi Institute for Drug Research, and Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences,
Tehran, Iran
b Endocrine and Metabolism Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
c Department of Tissue Engineering and Cell Therapy, School of Advanced Sciences in Medicine, Tehran University of Medical
Sciences, Tehran, IranReceived 1 July 2011; revised 4 September 2011; accepted 29 December 2011*
+
EKEYWORDS
Endoplasmic reticulum
stress;
White to brown adipocytes;
SalubrinalCorresponding author at: De
98 21 88622523.
-mail addresses: sharifal@yah
2251-7294 ª 2012 p
URL: www.tums.ac
doi:http://dx.doi.orpartmen
oo.com,
ublished
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g/10.1016Abstract The brown adipose tissue (BAT) is an organ with the specialised function of intracellular
fat oxidation; in other words, brown fat points to a potential natural tool by which energy expen-
diture is being stimulated. Obesity is a serious illness which can lead to many medical complications
such as cardiovascular disorders. The BAT production, therefore, could be a promising therapeutic
strategy for managing obesity. While different approaches have been examined to generate brown
adipocytes from various precursor cells, no study has proposed an efﬁcient procedure for direct
trans-differentiation of white to brown adipocytes. Bone morphogenic protein (BMP)-7 is a possible
potential agent by which most of the main factors involved in induction of brown adipocytogenesis
such as early regulators of brown fat fate, positive regulatory domain containing 16 (PRDM16) and
peroxisome proliferator-activated receptor gamma (PPARc) coactivator-1 alpha (PGC-1a) are
stimulated, but the rate of success was not so promising. It has been documented that mature white
adipocytes exert endoplasmic reticulum stress response (ESR) and consequently unfolded protein
response (UPR) becomes activated for the purpose of ESR recovery since the ESR exceeds the
capacity of UPR to overcome the imposed stress, and in turn disables the cell to manage the protein
synthesis cascade including those required for BMP-7 induction of brown adipogenesis. This was
performed using three main ESR sensors: PKR-like endoplasmic reticulum kinase (PERK), inositol
requiring enzyme-1 (IRE-1) and activating transcription factor 6 alpha (ATF-6a) resulting int of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Tel./fax:
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The possible potentiating role of endoplasmic reticulum stress 59attenuation of protein translation by blocking the activation of transcriptional machinery of UPR
genes and the cell behaviour would also be changed towards apoptosis.
It may suggest and propose the hypothesis that pretreatment of the white adipocyte with an ESR
inhibitor such as salubrinal by reducing ESR and turning on the protein synthesis machinery
required for BMP-7 induction of brown adipogenesis cascade could provide a more efﬁcient and
successful method of transdifferentiation procedure of white to brown adipocytes.
ª 2012 published by Elsevier Ltd. on behalf of Tehran University of Medical Science.
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The prevalence of obesity is increasing worldwide resulting in
major health problems such as type 2 diabetes, ischaemic heart
disease, stroke and cancer. It is a necessity to ﬁnd safer medi-
cation to treat obese individuals [1] but the pure cure does not
currently exist. In all mammals, a multi-depot organ called the
adipose organ contains white and brown adipocytes [2]. While
white fat cells are specialised in storage of energy in the form of
triglycerides, brown adipocytes (BATs), catabolise free fatty
acids (FFAs) and consume stored energy as heat [3]. The re-
cent development of new concepts regarding the biology of
adipose tissue in mammals had led to the hope for a hot issue
highlighting BAT development in adults as a new challenge for
treatment of obesity and related diseases. There is evidence in
the last few years supporting the concept of an alteration in en-
ergy balance by converting white to brown adipose tissue [4].
Bone morphogenic proteins (BMPs), members of trans-
forming growth factor b super-family, are responsible for the
control of multiple key steps in embryonic development and
play an important role in differentiation [5] and appear to have
different roles in adipogenesis [6]. Some studies have proposedsponse) signaling pathway. End
zyme-1 (IRE-1), activating tranthat treatment of humans with BMP-7 or its molecular
mimetic may recruit and activate brown fat differentiation,
leading to an elevation in energy expenditure, and thereby pro-
viding a new avenue to combat obesity [7]. Although some
studies have accomplished BMP7-induced brown adipocyte
differentiation from various cell types such as C3H10T1/2 cells
(mesenchymal progenitor/stem cells) or brown preadipocytes
with standard adipogenic differentiation cocktail supple-
mented [7], as the number of the white adipocytes are not al-
tered, the person still predisposes to obesity since it is
documented that both increase in the number of cells through
adipocyte proliferation (hyperplasia) and increase in adipocyte
size (hypertrophy) lead to adipose tissue expansion [8]. The
question therefore will be, how the number and triglyceride
(TG) accumulation of white adipocytes could be reduced? In
vitro studies have demonstrated that BMP7 is able to differen-
tiate brown preadipocytes into brown adipocytes. Although
the plasticity of adipocytes is well documented, no study has
examined BMP7’s potential role on direct trans-differentiation
of white to brown adipocytes [9]. How could this be explained?
It may partly be due to the endoplasmic reticulum stress re-
sponse (ESR). ESR refers to the cellular condition presentoplasmic stress response (ESR), PKR-like endoplasmic reticulum
scription factor 6 (ATF-6), eukaryotic initiation Factor 2 alpha
60 A.M. Shariﬁ, S. Mottaghiwhen ER function is perturbed as a result of excess nutrient
imbalance, excessive lipid storage and insulin resistance
[10,11]. The above-mentioned ER-disturbing conditions could
cause ER to become overwhelmed and consequently unfolded
protein response (UPR) becomes activated for the purpose of
ESR recovery. However, if the ER could not overcome the im-
posed stress, it would change its behaviour by directing the cell
to apoptosis [12]. In this case, as a consequence of UPR acti-
vation, ER stress sensors or transducers on ER membrane,
including PERK, IRE-1 and ATF-6a, are activated (Fig. 1).
These three prototypical ER localised stress sensors make
the UPR main signalling systems resulting in attenuation of
protein translation by blocking its machinery and transcrip-
tional activation of UPR genes leading to restore proper func-
tion and reduce the pressure upon ER [13].
The hypothesis
As it is evidenced, a mature dysfunctional white adipocyte is
experiencing ESR; it may therefore be speculated as the possi-
ble reason for unsuccessfulness of the BMP7 in efﬁcient trans-
differentiation of a mature white to brown adipocytes in previ-
ous studies. It could also be explained that blockade of the
translation machinery inhibits functioning of the speciﬁc pro-
tein synthesis programme required for BMP7 induction of
brown adipocyte including induction of early regulators of
brown fat fate PRDM16 [14] and PGC-1a [15] playing an
important role in brown adipogenesis.
Accordingly, it could be hypothesised that the initial treat-
ment of the white adipocyte with an ESR inhibitor such as
salubrinal by reducing ESR and turning on the protein synthe-
sis machinery required for BMP-7 induction of brown adipo-
genesis cascade, and then applying BMP7, could provide a
more efﬁcient and a new approach for trans-differentiation
of white to brown adipocytes. Interestingly, some clinical evi-
dences support this hypothesis. Many recent reports demon-
strated that 4-PBA (phenylbutyric acid) stabilises protein
conformation in the ER and therefore repressing ESR and
activation of UPR both in vitro and in vivo [16–24]. These stud-
ies may provide a ground for the therapeutic approaches
aimed at targeting the ESR/UPR to reduce the risk of obesity
and its complications.
Evaluation of hypothesis
To test the theory, appropriate in vivo and in vitro models are
necessary. Especially in vitro models can be employed to eval-
uate the potential role of ESR inhibitors in turning a dysfunc-
tional into a functional adipocyte which is then more prone to
BMP7 induction of brown adipogenesis. If the results were
conﬁrmed, the hypothesis then could be tested in vivo by local
injection of adjusted amount of ESR inhibitors and BMP7
periodically into the adipose tissue of both NOD and STZ in-
duced-diabetic mice. It could also be possible to transplant a
scaffold with the property of controlled releasing of these
two substances in the adipose tissue of the affected individual.
Conclusion
In conclusion, it could be proposed the hypothesis that ESR
inhibitors can be used to produce a more efﬁcient BMP7induction of white to brown adipocyte trans-differentiation
by which it may provide potentially a simple and safe method
to combat obesity.
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First Question: What do we already know about the
subject?
The fact that BAT burns triglycerides (thermogenesis)
and also secretes fewer cytokines offers a potential strat-
egy to combat obesity by increasing brown fat formation
or inducing the trans-differentiation of WAT into BAT.
Several approaches are investigated regarding the promo-
tion of brown adipocytes from different cell sources,
which has been successful in MSC and brown preadipo-
cyte trials.
Second Question: What does your proposed theory add
to the current knowledge available, and what beneﬁts does
it have?
Direct in situ trans-differentiation of WAT to BAT
would bring more impressive therapeutic effects, as obes-
ity is caused by both hyperplasia and hypertrophy of
white adipocytes. Therefore, proposing an idea to target
white preadipocytes and exit them from this impaired cy-
cle to a condition which is almost specialised in burning
calories instead of storing calories is of great value with
the purpose of treating obesity and preventing its related
complications.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
To investigate the potential role of ESR inhibitors on
accelerating the BMP7 induction of brown adipogenesis,
it is recommended to perform both in vivo and in vitro
experiments using different ESR inhibitors such as 4-
PBA and salubrinal. For in vivo experiments, local injec-
tion of an adjusted amount of ESR inhibitors and
BMP7 periodically into the adipose tissue of obese mice
is proposed. Studies can be performed by transplantation
of slow-release biomaterials contained in our proposed
drugs in suitable subjects such as obese mice. The idea
can also be tested in vitro by culturing white preadipocytes
and treating them with appropriate concentrations and
time periods of BMP7 co-administered with ESR
inhibitors.References
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